CRITICAL INNOVATIONS LLC — Department of Defense SBIR Phase II: DHA213-009
CRITICAL INNOVATIONS LLC — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $1,100,000 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Topic code DHA213-009 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $1,100,000
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase II
- Topic
- DHA213-009
- Solicitation
- 21.3
- NAICS
- —
- Place of performance
- CA
- Period
- 2023-02-24 → 2025-03-07
Description
The Defense Health Agency seeks to develop a novel wearable wound infection treatment delivery device capable of delivering treatment for the prevention of infection in a prolonged care setting. Critical Innovations, NDA Partners, IOTAI, and consultants Loren Miller, MD, MPH, Gary Fong, PharmD, BCPS, BCIDP, Captain David Tanen, MD, FAAEM, FACMT (USN, Ret.), and former Commander Denise Whitfield, MD, FACET (USN), have formed a team of experts to address this important need. During Phase II, our objectives will be to further advance the innovative Rx-Shooter product. This will include: 1) Production of a refined prototype using an agile engineering approach; 2) Development of a manufacture-ready device; 3) Performance of additional studies to demonstrate product stability and efficacy; 4) Performance of a pilot Rx-Shooter study in a live-animal model; and 5) Maintenance of all regulatory compliance requirements while preparing for upcoming regulatory and transition hurdles.